Larimar Therapeutics price target lowered to $10 from $13 at Baird

Baird lowered the firm’s price target on Larimar Therapeutics (LRMR) to $10 from $13 and keeps an Outperform rating on the shares. Th efirm updated its model following Q4 results which showed the FDA is open to Skin FXN as a surogate endpoint with a BLA planned by year-end 2025.